With a new pri­ma­ry end­point and the dis­ap­pear­ance of a tri­al site, tiny Rit­ter claims a big clin­i­cal vic­to­ry

Over the last few weeks, tiny LA-based Rit­ter Phar­ma­ceu­ti­cals $RT­TR has changed the pri­ma­ry end­point and re­cal­cu­lat­ed the da­ta for its crit­i­cal Phase IIb/III study of its sole clin­i­cal as­set. But on Tues­day evening the cash-strapped nanocap biotech de­clared a win, trig­ger­ing a (tem­po­rary) surge in its stock price.

If you look at all 368 pa­tients in the study, says Rit­ter, the top-line re­sults found a 40% re­sponse for its lac­tose in­tol­er­ance drug RP-G28 and a 31% re­sponse for the place­bo arm. That was not sta­tis­ti­cal­ly sig­nif­i­cant. But…

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.